Krishnan Suma sold $75K of KRYS
Krishnan Suma (President, R&D) sold 240 shares of Krystal Biotech, Inc. (KRYS) at $311.65 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure adds incremental datapoints on insider behavior (sale size, price, remaining holdings) but does not introduce new operational, clinical, or financial information.
Market read
A planned insider sale is typically a low-signal event; any trading impact is likely limited unless it fits a broader pattern of selling.
What to watch
Traders may miss that the filing date is later than the trade date (sale occurred 2026-06-04), so any price reaction may reflect disclosure timing rather than new fundamentals.
Background
The filing is an SEC Form 4 insider transaction by Krystal Biotech’s President, R&D, including that it was executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Krystal Biotech insider (President, R&D) sold 240 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any reaction should be modest unless unusual follow-on selling appears.
Form 4 provides a specific sale price/date and confirms a pre-arranged plan, which typically reduces interpretive weight versus unscheduled selling.
Market effects
Minimal; this is company-specific insider activity without broader sector/regulatory implications.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, the market may overreact; the disclosure could be routine liquidity rather than negative information.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the SEC Form 4 insider sale disclosure.
- insiderKrishnan Suma
President, R&D; sold 240 shares at $311.65/share under a 10b5-1 plan.
